BIO
ReciBioPharm has developed a robust recombinant adeno-associated virus manufacturing platform that is applicable across a wide range of serotypes and genome sizes commonly seen in clinical development today. The platform uses targeted one-factor-at-a-time (OFAT) studies and multivariate design-of-experiments (DOE) methodologies to allow ReciBioPharm to meet the needs for viral vectors in the market today.
Fill up the form below and read the insight.